(CRDF) Cardiff Oncology, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CRDF) Cardiff Oncology, Inc. Complete Analysis Pack
Unlock Strategic Clarity
This Cardiff Oncology, Inc. BCG Matrix is a company-specific strategy tool that helps you see how its products or business units may fit into the four classic quadrants: Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual report content, so you can review the format and depth before buying. Purchase the full version to get the complete ready-to-use analysis.
Stars
Onvansertib, oral PLK1 inhibitor
Onvansertib is Cardiff Oncology, Inc.'s lead asset and main value driver, so it fits the closest BCG "Star" profile in a biotech pipeline. The oral PLK1 inhibitor remains at the center of the story, with growth tied to late-stage clinical readouts and how well the company can convert that data into partnering or funding support. If the next data stay positive, the asset could scale from a single-program focus into a broader commercial case.
Metastatic colorectal cancer, lead indication
Metastatic colorectal cancer is Cardiff Oncology, Inc.’s lead indication and the clearest Stars candidate in its BCG mix. CRC remains a major oncology burden, with about 1.9 million new cases and 900,000 deaths worldwide in 2022, and roughly 20% of patients present with metastatic disease at diagnosis. Ongoing trial updates keep mCRC at the center of value creation and make it the most likely path to partnering or commercialization.
TROV-054, Phase 1b/2
TROV-054 is an active Phase 1b/2 study of onvansertib, so it sits in Cardiff Oncology, Inc.'s "Star" bucket: high growth, high optionality. Phase 1b/2 data can move the stock fast, and it supports the lead-pipeline story plus near-term catalyst flow as the program advances.
FOLFIRI plus bevacizumab combination
FOLFIRI plus bevacizumab is the core comparator in Cardiff Oncology, Inc.'s mCRC plan, because it anchors onvansertib to a standard, guideline-used backbone. That gives the program clearer clinical relevance and a faster path to showing benefit versus current care. If response and progression data hold up, the combo can support a stronger commercial case for onvansertib.
- Standard mCRC backbone
- Raises trial relevance
- Can de-risk market adoption
KRAS-mutated patient segment
The KRAS-mutated colorectal cancer segment is a clear, defined target, and KRAS alterations appear in about 40% of colorectal cancers. In the U.S., the American Cancer Society projected about 154,000 new colorectal cancer cases and 53,000 deaths in 2025, which keeps the unmet need high.
- Defined patient pool, easier to target
- High unmet need supports pricing power
- Better than a broad cancer claim
For Cardiff Oncology, Inc., that makes the segment more attractive in a BCG Matrix view because precision oncology can win faster than undifferentiated oncology plays.
Onvansertib Could Drive Cardiff Oncology’s Next Growth Surge
Onvansertib is Cardiff Oncology, Inc.'s main Star: an oral PLK1 inhibitor tied to late-stage value creation in metastatic colorectal cancer. KRAS-mutated CRC gives a focused, high-need pool, and the company’s FOLFIRI plus bevacizumab backbone keeps the program clinically relevant. The lead asset can still scale if upcoming data stay positive.
| Star item | Key data |
|---|---|
| Onvansertib | Lead asset |
| mCRC | ~20% metastatic at diagnosis |
| KRAS-mut CRC | ~40% of CRC |
What is included in the product
Detailed Word Document
Cardiff Oncology’s BCG Matrix maps its pipeline units across Stars, Cash Cows, Question Marks, and Dogs to guide capital allocation.
Editable Excel File
One-page Cardiff Oncology BCG Matrix that quickly spots portfolio pain points and priorities.
Reference Sources
Provides a credible source trail for Cardiff Oncology, Inc., helping teams verify claims fast and make better decisions.
Cash Cows
0 approved products
Cardiff Oncology, Inc. has 0 approved products, so it does not have a marketed drug or steady product revenue. In BCG terms, that means it has no true cash cow to fund growth from internal cash flow. The company still depends on capital markets and cash reserves, not a mature commercial franchise.
0 recurring product sales
Cardiff Oncology, Inc. is still clinical-stage and reported no commercial drug sales in its latest filings, so Cash Cows are effectively absent. With 0 recurring product revenue, there is no stable cash-generating franchise to fund trials or operations, keeping the company reliant on equity raises, debt, and other financing rather than self-funding.
Cash and cash equivalents
Cardiff Oncology, Inc.’s cash and cash equivalents are the main operating buffer, funding clinical trials, payroll, and G&A costs, not a product cash cow. As a pre-revenue oncology biotech, its cash supports execution and buys time to reach data milestones. The latest reported balance should be checked in the most recent 10-Q or 10-K before sizing runway.
Equity financing
Cardiff Oncology, Inc. has leaned on public-market equity financing to fund operations, which is common for a small biotech with no commercial product sales in FY2025. This keeps cash on hand for clinical work and R&D while the pipeline is still pre-revenue. The tradeoff is dilution, but it remains the most practical liquidity source.
- Primary funding source: equity raises
- Supports uncommercialized pipeline
- Limits near-term liquidity risk
- Increases dilution pressure
Lean operating base
Cardiff Oncology operates as a clinical development company, so its fixed-asset base is light versus a maker-heavy biotech. In its Q1 2025 filing, Company Name reported about $67 million in cash, cash equivalents, and marketable securities, with no product revenue, so a lean operating base helps stretch runway. That is why this fits Cash Cows logic: low capital needs can preserve cash while trials run.
- Light assets, lower cash burn
- No commercial revenue yet
- Cash runway matters most
Cardiff Oncology Has No Cash Cow—Only Trial-Funding Liquidity
Cardiff Oncology, Inc. has no true Cash Cow because it had no product revenue in FY2025 and remains clinical-stage. Its main liquidity cushion was about $67 million in cash, cash equivalents, and marketable securities in Q1 2025, which supports trials but does not create steady operating cash flow. So, Cash Cows are absent and funding still comes from capital raises.
| Metric | FY2025 / Q1 2025 |
|---|---|
| Product revenue | 0 |
| Cash, cash eq., marketable securities | About $67 million |
| BCG Cash Cow status | Absent |
Get Your Copy
Cardiff Oncology, Inc. Reference Sources
The Cardiff Oncology, Inc. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No placeholders or sample pages—just the complete, professionally formatted file. Once purchased, it’s ready to download and use right away.
Dogs
Legacy Trovagene diagnostics business
Cardiff Oncology, Inc. began as Trovagene, Inc., but the legacy diagnostics business is no longer the growth engine. In BCG terms, this is a Dog: low share, weak momentum, and little strategic pull. Cardiff Oncology now focuses on oncology drug development, so the old diagnostics line is non-core and should be harvested or exited.
Rebrand completed in 2012
The 2012 rebrand to Cardiff Oncology, Inc. marked a clear pivot away from the earlier platform, and that old model no longer drives the business. Rebranding did not create revenue; Cardiff Oncology remains clinical-stage with $0 product revenue, so this chapter fits the "Dog" box in BCG terms. The name change shows strategy shift, not cash flow.
No commercial oncology portfolio
Cardiff Oncology, Inc. still has no approved oncology product, so commercial share is effectively 0%. With product revenue at $0 and no market sales growth, this fits classic Dog territory in the BCG Matrix. The lack of a marketed therapy means there is no current cash engine from oncology commercialization.
Operating losses
Cardiff Oncology, Inc. stays in the Dogs bucket because it is still pre-revenue and keeps funding R and D ahead of any product cash flow. In its latest filing, that means losses keep draining capital while the company waits on clinical proof. That is value-negative until a pipeline win turns into sales.
- Pre-revenue, so no offsetting sales.
- R and D spending drives the cash burn.
- Losses tie up capital for years.
- Value improves only after a success.
Small public biotech scale
Cardiff Oncology, Inc. is still a small public biotech, so its Dogs bucket reflects scale limits: no commercial oncology revenue yet, and progress depends on clinical readouts plus access to capital. That leaves weak programs with little room to become cash generators without a bigger sales base.
Its model is built on pipeline optionality, not operating leverage, so financing risk stays high until data can support partnering or approval.
- Small scale limits cash flow.
- Clinical milestones drive valuation.
- Capital access remains essential.
- No commercial scale, no leverage.
Cardiff Oncology: A Clinical-Stage Dog With No Revenue Yet
Cardiff Oncology, Inc. stays a Dog in BCG terms because it has no approved oncology product, $0 product revenue, and no commercial share. In 2025, the business still depended on R and D spending and outside capital, so the legacy diagnostics line and the current pipeline both lack cash-generation power. That leaves value tied to future trial wins, not current sales.
| Metric | Value |
|---|---|
| Product revenue | $0 |
| Commercial share | 0% |
| Status | Clinical-stage |
Question Marks
CY140, PLK1/2/3 inhibitor
CY140 is still in Phase 1/2, so it fits the Question Mark box: high upside, but the market fit is not proven yet. Cardiff Oncology, Inc. has 0 approved CY140 products and no commercial revenue from this asset, so adoption and value remain uncertain. Until clinical data turn into clear efficacy and safety wins, the payoff is still speculative.
CY140 in solid tumors
CY140 in solid tumors can widen Cardiff Oncology, Inc.'s reach beyond one indication, so the addressable market can grow fast if the data hold. But that same move also lifts clinical risk, since each tumor type can need its own proof of response, dosing, and safety. Commercial upside is still unproven, so this stays a Question Mark until larger, late-stage data land.
CY140 in leukemias
CY140 now has 2 disease paths, with leukemia joining the solid-tumor work. That gives Cardiff Oncology, Inc. more optionality, but the leukemia study is still early and has no proven efficacy yet. Until response data and durability are clear, it stays a Question Mark.
TROV-053, Phase II
TROV-053 is still a Phase II clinical program, so it sits in Cardiff Oncology, Inc.’s Question Marks bucket: high upside, but no approval yet and no proven commercial cash flow. Phase II assets only move toward Stars if response data are strong, and the success odds are still uncertain. Cardiff Oncology, Inc. reported $32.0 million in cash and equivalents at 2025 year-end, so funding and trial readouts matter.
- Phase II only; no approval
- Upside depends on response data
- Success probability remains uncertain
Zytiga combination in mCRPC
Cardiff Oncology's onvansertib plus Zytiga in metastatic castration-resistant prostate cancer is a real growth bet, but it is still early-stage and not a proven franchise. The mCRPC market is large, with about 10% to 20% of metastatic prostate cancer patients developing this state, so a positive signal could open a meaningful niche. Combination trials can expand reach, but attrition risk stays high until efficacy and tolerability hold up.
- mCRPC is a high-value but tough market.
- Onvansertib still needs clinical proof.
- Success could unlock combo-based growth.
- Failure would keep it a Question Mark.
Cardiff Oncology's early bets need phase 2 proof
Cardiff Oncology, Inc.'s Question Marks are still early-stage bets: CY140, TROV-053, and onvansertib in mCRPC all lack approval and proven revenue. Cardiff Oncology, Inc. ended 2025 with $32.0 million in cash and equivalents, so the key trigger is clear phase 2 data, not sales. Upside is real, but proof is still missing.
| Asset | Status | 2025/2026 signal |
|---|---|---|
| CY140 | Phase 1/2 | No approval; no revenue |
| TROV-053 | Phase II | No approval; cash $32.0m |
| Onvansertib mCRPC | Early combo bet | High market, unproven fit |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.